Comparison of Outcomes of Management of Bowel Obstruction Pilot Study
Launched by UNIVERSITY OF WASHINGTON · Feb 4, 2025
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Millions of Americans each year experience adhesion-related small bowel obstruction (aSBO), a condition associated with significant morbidity and prolonged hospitalization. Adhesions formed after previous abdominopelvic surgery can cause twisting of the bowel resulting in injury and a cascade of inflammation that results in progressive bowel wall edema with narrowing of the bowel lumen. This leads to or worsens the bowel obstruction. Reversing this inflammation has the potential to reduce the severity and impact of aSBO, hasten the return of bowel function and avoid an emergency operation t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults ≥18 years of age recruited from UWMC
- • Patients presenting to surgical services through the Emergency Department, diagnosis of SBO, consulted by surgeon, and an urgent or emergency operation is deemed not necessary by surgeon.
- • Diagnosis of aSBO is established by;
- • 1. CT findings consistent with diagnosis of SBO; and
- • 2. signs and symptoms consistent with SBO; and
- • 3. Adhesions are the likely cause of SBO (absence of incarcerated hernia, internal hernia, masses, fistula, stricture, volvulus, acute episode of inflammatory bowel disease (IBD) flare, etc.).
- • Ability to provide written or electronic informed consent in English and answer teach-back questions
- Exclusion Criteria:
- • Signs and symptoms of peritonitis with emergency operation planned
- • Planned urgent operation within the next 12 hours
- • Allergy to dexamethasone
- • Surgery within prior 6 weeks
- • Unable or unwilling to return or be contacted for and/or complete research surveys
- • Currently incarcerated in a detention facility or in police custody (patients wearing a monitoring device can be enrolled) at baseline/screening
- • Individuals with latent infections who have an increased risk of infection.
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
David Flum, MD, MPH
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported